CHENGDU, China, Dec. 26, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company is engaged in discussion with a pharmaceutical industry strategic partner to form an Alliance (the "Alliance") in building a nationwide mTCM portfolio platform. We expect the Alliance to be based at TPI's new Qionglai Tianyin Facility (QLF) as the core entity with TPI's current product portfolio to drive the growth of the Company with a more focused effort to TPI's core product portfolio, an expanded national footprint and the opportunity to integrate both the upstream and downstream client base.
The outline of the initiative is described as follows:
-- Two Companies to form an Alliance to integrate and synergize the sales network to reach over 10,000 hospitals nationwide, 10 fold increase from TPI's current 1,000 own network hospitals;
-- The Alliance is expected to transform TPI's portfolio landscape by creating a multifaceted platform that focuses on cardiovascular franchise led by TPI's revenue driver, Gingko Mihuan Oral Liquid (GMOL);
-- Optimize the market penetration for other potential revenue drivers amongst TPI's comprehensive product portfolio.
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API with main manufacturing facilities at Qionglai County, Qionglai Tianyin Facility (QLF) and a nationwide distribution network. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
SOURCE Chengdu Tianyin Pharmaceutical Co., Inc.